Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Type I Diabetes
Interventions
NNC0361-0041, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Conditions
Obesity
Interventions
recombinant human growth hormone (rhGH), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes
Interventions
MMT 723
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 23 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
inhaled human insulin, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Renton, Washington
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled human insulin (EXUBERA™)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
34
States / cities
Burlingame, California • Irvine, California • Los Angeles, California + 31 more
Completed No phase listed Observational Results available

Follow-Up Study for Exubera

NCT00734591
Conditions
Diabetes Mellitus
Interventions
Exubera, Randomized diabetes therapy
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
7,439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
131
States / cities
Bay Minette, Alabama • Graysville, Alabama • Pell City, Alabama + 111 more
Conditions
Type 2 Diabetes Mellitus
Interventions
HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
117
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more
Conditions
Type 1 Diabetes Mellitus
Interventions
HDV Insulin Lispro, Insulin LISPRO
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Corona, California • Los Angeles, California • Northridge, California + 18 more
Conditions
Type 1 Diabetes
Interventions
FCL+BPS, FCL
Device
Lead sponsor
Marc Breton
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 6 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Volagidemab
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Deigo, California • Walnut Creek, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Lispro, Insulin Aspart
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 9 more
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Autoinjector
Drug · Device
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more
Conditions
Acromegaly
Interventions
ALXN2420, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Torrance, California • Ann Arbor, Michigan
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Fatty Liver Disease, Nonalcoholic
Interventions
metreleptin
Drug
Lead sponsor
Elif Oral
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

ADRB3 Signaling Pathway in Human Adipose Tissue

NCT05634174
Conditions
Obesity, Prediabetes
Interventions
Mirabegron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Conditions
Hypogonadism
Interventions
GnRH antagonist (Acyline)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts